Bromodomain inhibitors

Patent metadata

Field	Value
Publication number	US-10633379-B2
Application number	US-201716093483-A
Country	US
Kind code	B2
Filing date	Apr 14, 2017
Priority date	Apr 15, 2016
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

The present invention provides for compounds of formula (I)

wherein R 1 , R 2 , R 3 , R 4 , R 6 , X 1 , and X 2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

First claim

The invention claimed is:

1. N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide or a pharmaceutically acceptable salt thereof.

2. N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide.

Assignees

• Abbvie Inc

Inventors

• Hasvold Lisa A
• Liu Dachun
• Mcdaniel Keith F
• PRATT John
• SHEPPARD George
• Wang Le

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title